Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years. NAME Mepolizumab (Nucala) and Reslizumab (Cinqair)
APPROVED FOR
Adult and adolescent patients with eosinophilic asthma TYPE Mepolizumab (fully humanized IgG1κ); Reslizumab (fully humanized IgG4κ)
MOLECULAR TARGETS
Interleukin-5
CELLULAR TARGETS
Eosinophils, white blood cells that promote an excessive inflammatory response in allergies, are born in the bone marrow, relocate into blood vessels, and traffic to tissues such as the lung. The growth, activation, and survival of these cells are suppressed systemically by anti-IL-5 treatment.
EFFECTS ON TARGETS
Anti-IL-5 antibodies block binding of the cytokine IL-5 to the α chain of the IL-5 receptor complex on the eosinophil cell surface, thereby reducing the levels and activation status of eosinophils.
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